HKI 357

Discontinued Product

3580 has been discontinued.

View all EGFR products.
说明: Dual irreversible inhibitor of ErbB2 and EGFR
化学名: (2E)-N-[[4-[[(3-Chloro-4-[(3-fluorophenyl)methoxy]phenyl]amino]-3-cyano-7-ethoxy-6-quinolinyl]-4-(dimethylamino)-2-butenamide
纯度: ≥98% (HPLC)
说明书
引用文献
评论
文献 (1)

生物活性 for HKI 357

HKI 357 is a potent, irreversible inhibitor of ErbB2 (HER2) and EGFR (IC50 values are 33 and 34 nM respectively). Suppresses ligand-induced EGFR autophosphorylation and cell proliferation in NCI-H1975 cells containing L858R and T790M mutations. Circumvents mechanisms of resistance to Iressa (Cat. No. 3000) in non-small-cell lung cancer cells.

技术数据 for HKI 357

分子量 574.05
公式 C31H29ClFN5O3
储存 Store at -20°C
纯度 ≥98% (HPLC)
CAS Number 848133-17-5
PubChem ID 11238512
InChI Key NERXPXBELDBEPZ-RMKNXTFCSA-N
Smiles O=C(/C=C/CN(C)C)NC1=C(OCC)C=C(N=CC(C#N)=C2NC3=CC=C(OCC4=CC=CC(F)=C4)C(Cl)=C3)C2=C1

上方提供的技术数据仅供参考。批次相关数据请参见分析证书。

Tocris products are intended for laboratory research use only, unless stated otherwise.

产品说明书 for HKI 357

分析证书/产品说明书
选择另一批次:

按产品操作查看相关产品

查看全部 EGFR Inhibitors

关键词: HKI 357, HKI 357 supplier, HKI357, EGFR, epidermal, growth, factor, receptors, inhibitors, inhibits, irreversible, dual, potent, ErbB2, HER2, 3580, Tocris Bioscience

篇 HKI 357 的引用文献

引用文献是使用了 Tocris 产品的出版物。

目前没有 HKI 357 的引用文献。

HKI 357 的评论

目前没有该产品的评论。 Be the first to review HKI 357 and earn rewards!

Have you used HKI 357?

Submit a review and receive an Amazon gift card.

$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image

$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

该领域的文献

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!

*请注意,Tocris 仅会向正规科研企业/机构地址发送文献。


Angiogenesis in Cancer Poster

Angiogenesis in Cancer Poster

This poster summarizes the pathogenesis of angiogenesis in cancer, as well as some of the main angiogenesis therapeutic targets.